Novo Nordisk announced October 2, 2026, that FDA has told the company its review of the biologics license application (BLA) for denecimig, a treatment for hemophilia A with or without inhibitors in adults and children, is still ongoing, with no new timeline communicated for regulatory action.¹ FDA said ongoing facility remediation activities, not the clinical data submitted in the BLA, are the reason for the extended review.¹
Key facts
- Drug: Denecimig (FVIIIa mimetic bispecific antibody; Novo Nordisk)
- Indication: Hemophilia A, with or without inhibitors, in adults and children
- US regulatory status: BLA under FDA review since September 2025; review extended due to facility remediation
- Original anticipated US decision: 3rd quarter of 2026
- Target US launch: 1st half of 2027, pending FDA decision
- EU regulatory status: Positive CHMP opinion September 17, 2026; to be marketed as Frehemgo
- Clinical program: FRONTIER1-5 trials across monthly, every-2-week, and weekly dosing
- Key efficacy data: phase 3 FRONTIER2 showed up to 99% fewer bleeds vs on-demand treatment
Why is FDA's review taking longer than expected?
Novo submitted the denecimig BLA for review in September 2025, anticipating a regulatory decision in the 3rd quarter of 2026.¹ FDA subsequently conducted a prelicense inspection of the manufacturing site and provided feedback. The agency has now told Novo that remediation activities tied to that feedback are extending the review, without specifying a revised timeline.¹
"Hemophilia A patients should expect more from their standard of care," said Mike Doustdar, president and CEO of Novo, in a company press release.¹ "As Novo prepares to bring denecimig to market, our ambition is to help make better care something they can count on. Novo is already in the process of addressing [FDA's] requests as efficiently as possible and continuing to work closely with the agency toward bringing denecimig to patients in the US."
Does the delay reflect concerns about denecimig's safety or efficacy?
FDA has not identified any deficiencies related to the clinical efficacy or safety data submitted in the denecimig BLA.¹ That data draws on the FRONTIER clinical trial program, comprising FRONTIER1 through FRONTIER5, which evaluated denecimig as prophylaxis against bleeding episodes in pediatric and adult patients with hemophilia A, with or without inhibitors, across monthly, every-2-week, and weekly dosing regimens.¹
In the phase 3 FRONTIER2 trial, once-monthly dosing reduced bleeds by nearly 99% compared with on-demand treatment and by about 43% compared with patients' prior preventive factor therapy, while once-weekly dosing reduced bleeds by about 96% and 54%, respectively.² Novo said the manufacturing-site feedback does not affect its other marketed products.¹
What has happened with denecimig outside the United States?
FDA's review comes as denecimig advances in other markets. The drug received a positive opinion from the European Union's (EU) Committee for Medicinal Products for Human Use (CHMP) on September 17, 2026, recommending marketing authorization under the brand name Frehemgo for hemophilia A, with or without inhibitors, in adults and children. The candidate remains under review by other regulatory authorities.³
